<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://biosignaling.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Cell Communication and Signaling - Most accessed articles</title>
        <link>http://www.biosignaling.com</link>
        <description>The most accessed research articles published by Cell Communication and Signaling</description>
        <dc:date>2010-03-10T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biosignaling.com/content/8/1/3" />
                                <rdf:li rdf:resource="http://www.biosignaling.com/content/8/1/4" />
                                <rdf:li rdf:resource="http://www.biosignaling.com/content/7/1/18" />
                                <rdf:li rdf:resource="http://www.biosignaling.com/content/8/1/2" />
                                <rdf:li rdf:resource="http://www.biosignaling.com/content/7/1/20" />
                                <rdf:li rdf:resource="http://www.biosignaling.com/content/7/1/27" />
                                <rdf:li rdf:resource="http://www.biosignaling.com/content/8/1/1" />
                                <rdf:li rdf:resource="http://www.biosignaling.com/content/7/1/12" />
                                <rdf:li rdf:resource="http://www.biosignaling.com/content/7/1/25" />
                                <rdf:li rdf:resource="http://www.biosignaling.com/content/7/1/6" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biosignaling.com/content/8/1/3">
        <title>Dystroglycan versatility in cell adhesion: a tale of multiple motifs</title>
        <description>Dystroglycan is a ubiquitously expressed heterodimeric adhesion receptor. The extracellular &#945;-subunit makes connections with a number of laminin G domain ligands including laminins, agrin and perlecan in the extracellular matrix and the transmembrane &#946;-subunit makes connections to the actin filament network via cytoskeletal linkers including dystrophin, utrophin, ezrin and plectin, depending on context. Originally discovered as part of the dystrophin glycoprotein complex of skeletal muscle, dystroglycan is an important adhesion molecule and signalling scaffold in a multitude of cell types and tissues and is involved in several diseases. Dystroglycan has emerged as a multifunctional adhesion platform with many interacting partners associating with its short unstructured cytoplasmic domain. Two particular hotspots are the cytoplasmic juxtamembrane region and at the very carboxy terminus of dystroglycan. Regions which between them have several overlapping functions: in the juxtamembrane region; a nuclear localisation signal, ezrin/radixin/moesin protein, rapsyn and ERK MAP Kinase binding function, and at the C terminus a regulatory tyrosine governing WW, SH2 and SH3 domain interactions. We will discuss the binding partners for these motifs and how their interactions and regulation can modulate the involvement of dystroglycan in a range of different adhesion structures and functions depending on context. Thus dystroglycan presents as a multifunctional scaffold involved in adhesion and adhesion-mediated signalling with its functions under exquisite spatio-temporal regulation.</description>
        <link>http://www.biosignaling.com/content/8/1/3</link>
                <dc:creator>Chris Moore</dc:creator>
                <dc:creator>Steve Winder</dc:creator>
                <dc:source>Cell Communication and Signaling 2010, 8:3</dc:source>
        <dc:date>2010-02-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1478-811X-8-3</dc:identifier>
        <prism:publicationName>Cell Communication and Signaling</prism:publicationName>
        <prism:issn>1478-811X</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2010-02-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biosignaling.com/content/8/1/4">
        <title>Beyond journal impact factors?</title>
        <description>-</description>
        <link>http://www.biosignaling.com/content/8/1/4</link>
                <dc:creator>Stephan Feller</dc:creator>
                <dc:source>Cell Communication and Signaling 2010, 8:4</dc:source>
        <dc:date>2010-03-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1478-811X-8-4</dc:identifier>
        <prism:publicationName>Cell Communication and Signaling</prism:publicationName>
        <prism:issn>1478-811X</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2010-03-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biosignaling.com/content/7/1/18">
        <title>Regulation of MicroRNA Biogenesis:
A miRiad of mechanisms
</title>
        <description>microRNAs are small, non-coding RNAs that influence diverse biological functions through the repression of target genes during normal development and pathological responses. Widespread use of microRNA arrays to profile microRNA expression has indicated that the levels of many microRNAs are altered during development and disease. These findings have prompted a great deal of investigation into the mechanism and function of microRNA-mediated repression. However, the mechanisms which govern the regulation of microRNA biogenesis and activity are just beginning to be uncovered. Following transcription, mature microRNA are generated through a series of coordinated processing events mediated by large protein complexes. It is increasingly clear that microRNA biogenesis does not proceed in a &apos;one-size-fits-all&apos; manner. Rather, individual classes of microRNAs are differentially regulated through the association of regulatory factors with the core microRNA biogenesis machinery. Here, we review the regulation of microRNA biogenesis and activity, with particular focus on mechanisms of post-transcriptional control. Further understanding of the regulation of microRNA biogenesis and activity will undoubtedly provide important insights into normal development as well as pathological conditions such as cardiovascular disease and cancer.</description>
        <link>http://www.biosignaling.com/content/7/1/18</link>
                <dc:creator>Brandi Davis</dc:creator>
                <dc:creator>Akiko Hata</dc:creator>
                <dc:source>Cell Communication and Signaling 2009, 7:18</dc:source>
        <dc:date>2009-08-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1478-811X-7-18</dc:identifier>
        <prism:publicationName>Cell Communication and Signaling</prism:publicationName>
        <prism:issn>1478-811X</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>18</prism:startingPage>
        <prism:publicationDate>2009-08-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biosignaling.com/content/8/1/2">
        <title>Signal transduction, receptors, mediators and genes: younger than ever - the 13th meeting of the Signal Transduction Society focused on aging and immunology</title>
        <description>The 13th meeting of the Signal Transduction Society was held in Weimar, from October 28 to 30, 2009. Special focus of the 2009 conference was &quot;Aging and Senescence&quot;, which was co-organized by the SFB 728 &quot;Environmentally-Induced Aging Processes&quot; of the University of D&#252;sseldorf and the study group &apos;Signal Transduction&apos; of the German Society for Cell Biology (DGZ). In addition, several other areas of signal transduction research were covered and supported by different consortia associated with the Signal Transduction Society including the long-term associated study groups of the German Society for Immunology and the Society for Biochemistry and Molecular Biology, and for instance the SFB/Transregio 52 &quot;Transcriptional Programming of Individual T Cell Subsets&quot; located in W&#252;rzburg, Mainz and Berlin. The different research areas that were introduced by outstanding keynote speakers attracted more than 250 scientists, showing the timeliness and relevance of the interdisciplinary concept and exchange of knowledge during the three days of the scientific program. This report gives an overview of the presentations of the conference.</description>
        <link>http://www.biosignaling.com/content/8/1/2</link>
                <dc:creator>Frank Entschladen</dc:creator>
                <dc:creator>Joachim Altschmied</dc:creator>
                <dc:creator>Ria Baumgrass</dc:creator>
                <dc:creator>Iris Behrmann</dc:creator>
                <dc:creator>Klaudia Giehl</dc:creator>
                <dc:creator>Heike Hermanns</dc:creator>
                <dc:creator>Otmar Huber</dc:creator>
                <dc:creator>Arnd Kieser</dc:creator>
                <dc:creator>Lars-Oliver Klotz</dc:creator>
                <dc:creator>Katharina Kubatzky</dc:creator>
                <dc:creator>Ralf Hass</dc:creator>
                <dc:creator>Ottmar Janssen</dc:creator>
                <dc:creator>Karlheinz Friedrich</dc:creator>
                <dc:source>Cell Communication and Signaling 2010, 8:2</dc:source>
        <dc:date>2010-02-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1478-811X-8-2</dc:identifier>
        <prism:publicationName>Cell Communication and Signaling</prism:publicationName>
        <prism:issn>1478-811X</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2010-02-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biosignaling.com/content/7/1/20">
        <title>Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation</title>
        <description>Acetylcholine (ACh) has been shown to modulate neuronal differentiation during early development. Both muscarinic and nicotinic acetylcholine receptors (AChRs) regulate a wide variety of physiological responses, including apoptosis, cellular proliferation and neuronal differentiation. However, the intracellular mechanisms underlying these effects of AChR signaling are not fully understood. It is known that activation of AChRs increase cellular proliferation and neurogenesis and that regulation of intracellular calcium through AChRs may underlie the many functions of ACh. Intriguingly, activation of diverse signaling molecules such as Ras-mitogen-activated protein kinase, phosphatidylinositol 3-kinase-Akt, protein kinase C and c-Src is modulated by AChRs. Here we discuss the roles of ACh in neuronal differentiation, cell proliferation and apoptosis. We also discuss the pathways involved in these processes, as well as the effects of novel endogenous AChRs agonists and strategies to enhance neuronal-differentiation of stem and neural progenitor cells. Further understanding of the intracellular mechanisms underlying AChR signaling may provide insights for novel therapeutic strategies, as abnormal AChR activity is present in many diseases.</description>
        <link>http://www.biosignaling.com/content/7/1/20</link>
                <dc:creator>Rodrigo Resende</dc:creator>
                <dc:creator>Avishek Adhikari</dc:creator>
                <dc:source>Cell Communication and Signaling 2009, 7:20</dc:source>
        <dc:date>2009-08-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1478-811X-7-20</dc:identifier>
        <prism:publicationName>Cell Communication and Signaling</prism:publicationName>
        <prism:issn>1478-811X</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>20</prism:startingPage>
        <prism:publicationDate>2009-08-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biosignaling.com/content/7/1/27">
        <title>Leptin and Adiponectin: new players in the field of tumor cell and leukocyte migration</title>
        <description>Adipose tissue is no longer considered to be solely an energy storage, but exerts important endocrine functions, which are primarily mediated by a network of various soluble factors derived from fat cells, called adipocytokines. In addition to their responsibility to influence energy homeostasis, new studies have identified important pathways linking metabolism with the immune system, and demonstrating a modulatory role of adipocytokines in immune function. Additionally, epidemiological studies underline that obesity represents a significant risk factor for the development of cancer, although the exact mechanism of this relationship remains to be determined. Whereas a possible influence of adipocytokines on the proliferation of tumor cells is already known, new evidence has come to light elucidating a modulatory role of this signaling substances in the regulation of migration of leukocytes and tumor cells. The migration of leukocytes is a key feature to fight cancer cells, whereas the locomotion of tumor cells is a prerequisite for tumor formation and metastasis. We herein review the latest tumor biological findings on the role of the most prominent adipocytokines leptin and adiponectin, which are secreted by fat cells, and which are involved in leukocyte migration, tumor growth, invasion and metastasis. This review thus accentuates the complex, interactive involvement of adipocytokines in the regulation of migration of both leukocytes and tumor cells, and gives an insight in the underlying molecular mechanisms.</description>
        <link>http://www.biosignaling.com/content/7/1/27</link>
                <dc:creator>Kerstin Lang</dc:creator>
                <dc:creator>Janina Ratke</dc:creator>
                <dc:source>Cell Communication and Signaling 2009, 7:27</dc:source>
        <dc:date>2009-12-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1478-811X-7-27</dc:identifier>
        <prism:publicationName>Cell Communication and Signaling</prism:publicationName>
        <prism:issn>1478-811X</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>27</prism:startingPage>
        <prism:publicationDate>2009-12-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biosignaling.com/content/8/1/1">
        <title>High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cells</title>
        <description>The molecular heterogeneity of human cancer cells at the level of signaling protein activities remains poorly understood. Using a panel of 64 colorectal (CRC) cancer cell lines the activity status of the MAP kinases Erk1 and Erk2 was investigated. Erk1/2 activity varied greatly within the CRC cell line panel and was not detectably associated with the speed of cell growth in 10 CRC lines analyzed. As expected, mutations in K-Ras or B-Raf were often, albeit not always, linked to high Erk1/2 activity. The phosphorylation of several known Erk1/2 targets investigated did not generally reflect Erk1/2 activity in the 10 CRC lines analyzed. However, the reduction of Erk1/2 activity with MEK inhibitors generally abolished cell growth but only led to an increase of cellular p27Kip1 levels in CRC cells with high Erk1/2 activity levels. The results indicate that high Erk1/2 activation is utilized by some CRC lines to override the cell cycle brake p27Kip1, while others presumably rely on different mechanisms in order to inactivate this important cell cycle brake. Such detailed knowledge of the molecular diversity of cancer cell signaling mechanisms may eventually help to develop molecularly targeted, patient-specific therapeutic strategies and treatments.</description>
        <link>http://www.biosignaling.com/content/8/1/1</link>
                <dc:creator>Theresia Kress</dc:creator>
                <dc:creator>Thomas Raabe</dc:creator>
                <dc:creator>Stephan Feller</dc:creator>
                <dc:source>Cell Communication and Signaling 2010, 8:1</dc:source>
        <dc:date>2010-02-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1478-811X-8-1</dc:identifier>
        <prism:publicationName>Cell Communication and Signaling</prism:publicationName>
        <prism:issn>1478-811X</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2010-02-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biosignaling.com/content/7/1/12">
        <title>The receptor RAGE: Bridging inflammation and cancer</title>
        <description>The receptor for advanced glycation end products (RAGE) is a single transmembrane receptor of the immunoglobulin superfamily that is mainly expressed on immune cells, neurons, activated endothelial and vascular smooth muscle cells, bone forming cells, and a variety of cancer cells. RAGE is a multifunctional receptor that binds a broad repertoire of ligands and mediates responses to cell damage and stress conditions. It activates programs responsible for acute and chronic inflammation, and is implicated in a number of pathological diseases, including diabetic complications, stroke, atheriosclerosis, arthritis, and neurodegenerative disorders. The availability of Rage knockout mice has not only advanced our knowledge on signalling pathways within these pathophysiological conditions, but also on the functional importance of the receptor in processes of cancer. Here, we will summarize molecular mechanisms through which RAGE signalling contributes to the establishment of a pro-tumourigenic microenvironment. Moreover, we will review recent findings that provide genetic evidence for an important role of RAGE in bridging inflammation and cancer.</description>
        <link>http://www.biosignaling.com/content/7/1/12</link>
                <dc:creator>Astrid Riehl</dc:creator>
                <dc:creator>Julia Nemeth</dc:creator>
                <dc:creator>Peter Angel</dc:creator>
                <dc:creator>Jochen Hess</dc:creator>
                <dc:source>Cell Communication and Signaling 2009, 7:12</dc:source>
        <dc:date>2009-05-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1478-811X-7-12</dc:identifier>
        <prism:publicationName>Cell Communication and Signaling</prism:publicationName>
        <prism:issn>1478-811X</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2009-05-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biosignaling.com/content/7/1/25">
        <title>Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?</title>
        <description>The drugs cyclosporine A (CsA) and tacrolimus (FK506) revolutionized organ transplantation. Both compounds are still widely used in the clinic as well as for basic research, even though they have dramatic side effects and modulate other pathways than calcineurin-NFATc, too. To answer the major open question - whether the adverse side effects are secondary to the actions of the drugs on the calcineurin-NFATc pathway - alternative inhibitors were developed. Ideal inhibitors should discriminate between the inhibition of (i) calcineurin and peptidyl-prolyl cis-trans isomerases (PPIases; the matchmaker proteins of CsA and FK506), (ii) calcineurin and the other Ser/Thr protein phosphatases, and (iii) NFATc and other transcription factors. In this review we summarize the current knowledge about novel inhibitors, synthesized or identified in the last decades, and focus on their mode of action, specificity, and biological effects.</description>
        <link>http://www.biosignaling.com/content/7/1/25</link>
                <dc:creator>Matthias Sieber</dc:creator>
                <dc:creator>Ria Baumgrass</dc:creator>
                <dc:source>Cell Communication and Signaling 2009, 7:25</dc:source>
        <dc:date>2009-10-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1478-811X-7-25</dc:identifier>
        <prism:publicationName>Cell Communication and Signaling</prism:publicationName>
        <prism:issn>1478-811X</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>25</prism:startingPage>
        <prism:publicationDate>2009-10-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biosignaling.com/content/7/1/6">
        <title>Identification of subpopulations in mesenchymal stem cell-like cultures from human umbilical cord</title>
        <description>Background:
A variety of cell types can be identified in the adherent fraction of bone marrow mononuclear cells including more primitive and embryonic-like stem cells, mesenchymal stem cells (MSC), lineage-committed progenitors as well as mature cells such as osteoblasts and fibroblasts. Different methods are described for the isolation of single bone marrow stem cell subpopulations &#8211; beginning from ordinary size sieving, long term cultivation under specific conditions to FACS-based approaches. Besides bone marrow-derived subpopulations, also other tissues including human umbilical cord (UC) have been recently suggested to provide a potential source for MSC. Although of clinical importance, these UC-derived MSC populations remain to be characterized. It was thus the aim of the present study to identify possible subpopulations in cultures of MSC-like cells obtained from UC. We used counterflow centrifugal elutriation (CCE) as a novel strategy to successfully address this question.
Results:
UC-derived primary cells were separated by CCE and revealed differentially-sized populations in the fractions. Thus, a subpopulation with an average diameter of about 11 &#956;m and a small flat cell body was compared to a large sized subpopulation of about 19 &#956;m average diameter. Flow cytometric analysis revealed the expression of certain MSC stem cell markers including CD44, CD73, CD90 and CD105, respectively, although these markers were expressed at higher levels in the small-sized population. Moreover, this small-sized subpopulation exhibited a higher proliferative capacity as compared to the total UC-derived primary cultures and the large-sized cells and demonstrated a reduced amount of aging cells.
Conclusion:
Using the CCE technique, we were the first to demonstrate a subpopulation of small-sized UC-derived primary cells carrying MSC-like characteristics according to the presence of various mesenchymal stem cell markers. This is also supported by the high proliferative capacity of these MSC-like cells as compared to whole primary culture or other UC-derived subpopulations. The accumulation of a self-renewing MSC-like subpopulation by CCE with low expression levels of the aging marker senescence-associated &#946;-galactosidase provides a valuable tool in the regenerative medicine and an alternative to bone-marrow-derived MSC.</description>
        <link>http://www.biosignaling.com/content/7/1/6</link>
                <dc:creator>Ingrida Majore</dc:creator>
                <dc:creator>Pierre Moretti</dc:creator>
                <dc:creator>Ralf Hass</dc:creator>
                <dc:creator>Kasper Cornelia</dc:creator>
                <dc:source>Cell Communication and Signaling 2009, 7:6</dc:source>
        <dc:date>2009-03-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1478-811X-7-6</dc:identifier>
        <prism:publicationName>Cell Communication and Signaling</prism:publicationName>
        <prism:issn>1478-811X</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2009-03-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
